Protalix BioTherapeutics (PLX) Other Operating Expenses (2010 - 2026)
Protalix BioTherapeutics (PLX) posted quarterly Other Operating Expenses of -$7.2 million for Q1 2026, down 11936.67% year-over-year from N/an in Q1 2025, and down 10.58% quarter-over-quarter from -$6.5 million in Q4 2025.
Protalix BioTherapeutics (PLX) Other Operating Expenses (2010 - 2026) Analysis & Trends
Protalix BioTherapeutics' Other Operating Expenses history runs 13 years deep, the most recent figure standing at -$7.2 million for Q1 2026.
- In Q1 2026, Other Operating Expenses fell 11936.67% year-over-year to -$7.2 million; the TTM figure through Mar 2026 stood at -$17.3 million (down 630.16% YoY), while the FY2025 annual figure was -$10.3 million, down 38.02% from the prior year.
- Other Operating Expenses for Q1 2026 stood at -$7.2 million, down from -$6.5 million in the prior quarter.
- The five-year high for Other Operating Expenses was $1.8 million in Q3 2024, with the low at -$7.2 million in Q1 2026.
- The 3-year median for Other Operating Expenses is -$2.0 million (2025), against an average of -$2.5 million.
- The sharpest annual moves came in 2025 and 2026: Other Operating Expenses declined 25.0% in 2025, then plunged 11936.67% in 2026.
- Protalix BioTherapeutics' Other Operating Expenses stood at -$5.2 million in 2024, then retreated by 25.0% to -$6.5 million in 2025, then slipped by 10.58% to -$7.2 million in 2026.
- Business Quant data shows PLX's Other Operating Expenses at -$7.2 million in Q1 2026, -$6.5 million in Q4 2025, and $394000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Protalix BioTherapeutics | 189.97 Mn | 149.31 Mn | 12.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.63 Mn |
| Mar 31, 2026 | -7.22 Mn |
| Dec 31, 2025 | -6.53 Mn |
| Sep 30, 2025 | 394,000.00 |
| Jun 30, 2025 | -3.92 Mn |
| Mar 31, 2025 | -60,000.00 |
| Dec 31, 2024 | -5.23 Mn |
| Sep 30, 2024 | 1.76 Mn |
| Jun 30, 2024 | 1.16 Mn |
| Mar 31, 2019 | 3,000.00 |
| Dec 31, 2018 | 394,000.00 |
| Sep 30, 2018 | 732,000.00 |
| Jun 30, 2018 | 235,000.00 |
| Mar 31, 2018 | 843,000.00 |
| Dec 31, 2017 | 791,000.00 |
| Sep 30, 2017 | 729,000.00 |
| Jun 30, 2017 | 478,000.00 |
| Mar 31, 2017 | 1.34 Mn |
| Dec 31, 2016 | 1.00 Mn |
| Sep 30, 2016 | 1.30 Mn |